Becton, Dickinson and Company (BDX) Stock Analysis
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Becton, Dickinson and Company (BDX) is a leading medical technology company that appears to be fairly valued based on a DCF analysis, supported by its stable revenue growth and strategic acquisitions in the Health Care sector.
Investment Recommendation
Hold
Fair Value: $285.50
Current Price: $279.62
Upside/Downside: +2.1%
The DCF analysis suggests the stock is trading at a fair valuation, with an implied fair value close to the current market price. While the company's fundamental strength and growth prospects are positive, the current price does not offer a significant margin of safety.
Key Metrics
- Market Cap: $73.49B
- P/E Ratio: 36.45x
- Forward P/E: 25.19x
- Revenue Growth (YoY): 2.0%
- Net Margin: 10.3%
- ROE: 15.6%
- Debt/Equity: 0.68
- Dividend Yield: 0.87%
Strengths
- Global leader in numerous medical device and diagnostic categories, generating substantial revenue.
- Diversified revenue streams across different end markets and geographies, reducing reliance on any single product or region.
- Consistent track record of innovation and significant investment in R&D to maintain product leadership.
- History of successful strategic acquisitions that expand its product offerings and market reach.
Risk Factors
- Stringent regulatory environment for medical devices and pharmaceuticals, with potential for product recalls or delays in approvals.
- Intense competition from both large, established players and nimble start-ups in various segments.
- Challenges in integrating acquired companies and realizing anticipated synergies, which can impact profitability.
- Exposure to currency fluctuations and geopolitical risks affecting international sales and operations.